Weekly Spotlight - 31.10.24

The impact of various treatment strategies, biomarkers, and vitamin D levels on childhood-onset SLE management.

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

Implementing a T2T Strategy Enhances cSLE Management

Implementing a treat-to-target (T2T) strategy in managing childhood-onset systemic lupus erythematosus (cSLE) proved feasible and effective. It enhanced disease control, reduced damage, and increased remission rates. Despite challenges, the study suggests adopting T2T strategies in routine practice for better patient outcomes.

Mycophenolate mofetil cuts flare, lupus nephritis risks in systemic lupus erythematosus

Early treatment with mycophenolate mofetil (MMF) reduces severe flares and lupus nephritis in systemic lupus erythematosus (SLE). A study showed MMF, combined with prednisone and hydroxychloroquine, significantly lowered flare risks compared to the latter two alone. Further research is needed to balance benefits and potential harms.

Scientists Identify Key Biomarkers That May Predict Low-Dose IL-2 Treatment Efficacy in Systemic Lupus Erythematosus

Researchers have identified key biomarkers predicting the success of low-dose IL-2 treatment in systemic lupus erythematosus. Rash, complement 3 levels, and renal involvement are strong indicators. Combining IL-2 with mycophenolate mofetil enhances outcomes. This discovery supports personalised treatment, offering hope for improved patient care.

Highest, lowest vitamin D levels predict adverse pregnancy outcomes in lupus

Monitoring vitamin D levels in pregnant women with lupus is crucial. Both high and low levels increase risks of miscarriage and preterm delivery. A target range of 40-59 ng/mL is recommended. Regular checks and appropriate supplementation can help maintain this balance, supporting healthier pregnancy outcomes.

Health Spotlight’s Systemic Lupus Erythematosus is a Contentive publication in the Healthcare division